24 May 2013
Keywords: xenova/gsk, th-hsv, ph, ii, trial, disappoints, uk
Article | 12 October 2001
UK company Xenova says that results from the Phase II clinical efficacytrial of TA-HSV (a therapeutic vaccine designed for the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 October 2001
11 October 2001
© 2013 thepharmaletter.com